Press Release
July 6, 2016

PRESS: 6-Month Notice Ruling Could Raise the Price of Biosimilars (The American Journal of Managed Care)

William Jay, a partner in and co-chair of Goodwin’s Appellate Litigation Practice, and Elaine Blais, head of the Litigation Department in Goodwin’s Boston office, discuss a new court ruling that may create another hurdle for launching low-cost, biosimilar-versions of expensive biologicals. Jay and Blais also talk about why a federal appeals court overturned a previous ruling and decided that biosimilar manufacturers must provide the innovator company a 180-day notice only after receiving FDA-approval for its biosimilar product.

The full American Journal of Managed Care article here.